We are live on ! Find out more
JNJ icon

Johnson & Johnson

270.47 USD
+3.33
1.25%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
270.52
+0.05
0.02%
1 day
1.25%
5 days
-6.41%
1 month
4.28%
3 months
1.16%
6 months
17.94%
Year to date
30.44%
1 year
33.19%
5 years
69.36%
10 years
135.19%
 

About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Employees: 140,800

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 49%
Neutral 42.4%
Negative 8.6%
Neutral
24/7 Wall Street
19 hours ago
3 Reasons Dividend Aristocrats Belong in Your Roth IRA Before You Retire
At the 24% bracket, a $500,000 equal-weight position in three Dividend Aristocrats returns about $10,933 a year in dividends. In a taxable account, roughly $1,640 of that goes to the IRS every year at the 15% qualified rate.
3 Reasons Dividend Aristocrats Belong in Your Roth IRA Before You Retire
Neutral
Benzinga
21 hours ago
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses proprietary data and pattern recognition to highlight five stocks just under the surface that deserve attention.
Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet
Neutral
24/7 Wall Street
21 hours ago
5 Dividend Kings to Buy for Lifelong Income Before the End of November
Yield chasers keep learning the same lesson: A payout is only as durable as the cash flow behind it.
5 Dividend Kings to Buy for Lifelong Income Before the End of November
Neutral
Seeking Alpha
1 day ago
Dividend Champion, Contender, And Challenger Highlights: Week Of November 22
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Dividend Champion, Contender, And Challenger Highlights: Week Of November 22
Positive
24/7 Wall Street
1 day ago
These 4 Conservative Dow Jones Industrials Dividend Stocks Are Built for Sell-Offs
The Dow shed 1,100 points in a single session, and retirees leaning on dividend income are asking whether their payouts can survive the next drop.
These 4 Conservative Dow Jones Industrials Dividend Stocks Are Built for Sell-Offs
Negative
Zacks Investment Research
1 day ago
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Halozyme faces a legal setback in Germany as a court overturns an injunction against Merck's Keytruda SC, prompting a new patent lawsuit.
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Positive
24/7 Wall Street
1 day ago
Want Reliable Dividend Passive Income? These 5 Stocks Raise Their Payouts Year After Year
Passive income works best when the paycheck keeps raising itself. Procter & Gamble (NYSE:PG | PG Price Prediction) described its latest quarterly payout as its 70th consecutive year of dividend increases.
Want Reliable Dividend Passive Income? These 5 Stocks Raise Their Payouts Year After Year
Neutral
PRNewsWire
1 day ago
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 study TREMFYA demonstrated more than 2 times greater reduction in MRI-assessed inflammation versus placebo at Week 24 in the sacroiliac joints, which connect the lower spine to the pelvis and are responsible for pain and stiffness TREMFYA was evaluated in first-ever PsA study using objective MRI assessments to confirm and measure axial inflammation alongside patient-reported symptoms NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with active psoriatic arthritis and axial involvement (axial PsA).
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
Neutral
Zacks Investment Research
2 days ago
Stock Screening Made Simple: A Closer Look
Stock screening is commonly deployed by investors to 'cut through the noise.' The approach is especially useful when you're choosing from thousands of options, which can often overwhelm investors.
Stock Screening Made Simple: A Closer Look
Positive
The Motley Fool
2 days ago
Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care
Johnson & Johnson's JNJ-6143 posted excellent results in an early-stage clinical trial. For income investors, the real story is a Dividend King with a deep lineup and pipeline.
Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care
Price charts implemented using Lightweight Charts™